Longboard Pharmaceuticals Appoints Brandi L. Roberts as Main Economical Officer

Press launch articles from Globe Newswire. The AP news workers was not involved in its…

Press launch articles from Globe Newswire. The AP news workers was not involved in its development.

SAN DIEGO, Jan. 21, 2021 (World NEWSWIRE) — Longboard Pharmaceuticals, Inc., a scientific-phase biopharmaceutical firm targeted on building novel, transformative medicines for neurological ailments, now announced the appointment of Brandi L. Roberts as its Main Financial Officer.

“Brandi’s robust fiscal acumen and expertise inside the lifestyle sciences sector will be crucial as we place the firm for long-expression growth and progress our assets in a vary of neurological illnesses,” mentioned Kevin R. Lind, Longboard’s President and Main Government Officer. “I am delighted to welcome Brandi to the group.”

Earlier, Ms. Roberts served as Chief Monetary Officer of Lineage Cell Therapeutics, Inc. (LCTX) from January 2019 to January 2021. Prior to becoming a member of Lineage in January 2019, she served as Main Fiscal Officer of REVA Healthcare, Inc. because August 2017. Ms. Roberts formerly served as Chief Economic Officer of Mast Therapeutics, Inc. from January 2013 to April 2017, and as its Senior Vice President, Finance, from March 2011 to January 2013. Formerly, she held senior positions at Alphatec Backbone, Inc., Artes Healthcare, Inc., Stratagene Company, and Pfizer, Inc. Ms. Roberts currently serves as Chair of the Southern California Chapter of the Affiliation of Bioscience Fiscal Officers and has served on the Board of Temple Therapeutics BV considering the fact that November 2019. Ms. Roberts provides far more than 25 several years of community accounting and finance knowledge, which include 22 a long time at publicly traded pharmaceutical, healthcare know-how, and lifestyle science businesses to her placement. Ms. Roberts is a accredited community accountant with the Condition of California and gained her B.S. degree in business administration from the College of Arizona and her M.B.A. from the University of San Diego.

About Longboard Prescription drugs
Longboard Prescription drugs, Inc. (Longboard) is a medical-phase biopharmaceutical enterprise targeted on establishing novel, transformative medications for neurological diseases. Longboard was formed in January 2020 by Arena Prescription drugs, Inc. (Arena) to progress a portfolio of centrally acting product or service candidates made to be very selective for precise G protein-coupled receptors (GPCRs). Longboard’s tiny molecule solution candidates were being learned out of the exact same platform at Arena that signifies a culmination of additional than 20 yrs of GPCR research. Longboard is analyzing LP352, an oral, centrally performing, 5-hydroxytryptamine 2c receptor subtype superagonist, in enhancement for the likely remedy of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, total cannabinoid type 2 receptor agonist, in improvement for the likely remedy of neurodegenerative conditions affiliated with neuroinflammation induced by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in progress for the likely cure of central anxious program neuroinflammatory conditions.

Company Call:
Megan E. Knight
Head of Investor Relations 
[email protected]
[email protected]
619.592.9775